Brief: Polyrizon Submits Pre-Request For Designation To FDA For Pl-16 Viral Blocker
19/12/2025 14:02
Dec 19 (Reuters) - Polyrizon Ltd PLRZ.O: POLYRIZON SUBMITS PRE-REQUEST FOR DESIGNATION TO FDA FOR PL-16 VIRAL BLOCKER DESIGNED TO REDUCE THE EXPOSURE TO INFLUENZA AND COLD VIRUSES Source text: ID:nGNX7687SG Further company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polyrizon
See all newsBrief: Polyrizon Files For U.S. Patent Application To Expand Ip Moat Around Intranasal Drug-Delivery Platform
Brief: Polyrizon Advances Towards Human Clinical Trials Secures First U.S. Clinical Site For Nasarix™ Allergy Blocker Clinical Trial
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:58 AM
Enters Agreements For Registered Direct Offering Of Ordinary Shares And Pre-Funded Warrants
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America